Clincosm LogoSign in Get a demo

Infection, Human Immunodeficiency Virus

Showing 51 - 75 of 113
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Infection, Human Immunodeficiency Virus Trial (BMS-663068, Darunavir (DRV), Ritonavir (RTV))

Completed
  • Infection, Human Immunodeficiency Virus
  • (no location specified)
Aug 7, 2017

Infection, Human Immunodeficiency Virus Trial in Overland Park (DTG/ABC/3TC FDC DISPERSIBLE TABLET, EPZICOM (ABC/3TC), TIVICAY

Completed
  • Infection, Human Immunodeficiency Virus
  • DTG/ABC/3TC FDC DISPERSIBLE TABLET
  • +2 more
  • Overland Park, Kansas
    GSK Investigational Site
Aug 3, 2017

Infection, Human Immunodeficiency Virus Trial in Madison (GSK706769, Placebo)

Completed
  • Infection, Human Immunodeficiency Virus
  • Madison, Wisconsin
    GSK Investigational Site
Aug 2, 2017

Infection, Human Immunodeficiency Virus Trial in San Antonio (BMS-663068)

Completed
  • Infection, Human Immunodeficiency Virus
  • San Antonio, Texas
    GSK Investigational Site
Jul 25, 2017

Infection, Human Immunodeficiency Virus Trial in Miami, San Antonio (BMS-663068, Oral Contraceptive, Loestrin 1.5/30)

Completed
  • Infection, Human Immunodeficiency Virus
  • Miami, Florida
  • +1 more
Jul 25, 2017

Infection, Human Immunodeficiency Virus Trial in Lisburn (BMS-663068, BMS-626529)

Completed
  • Infection, Human Immunodeficiency Virus
  • Lisburn, United Kingdom
    GSK Investigational Site
Jul 18, 2017

Infection, Human Immunodeficiency Virus Trial in Buffalo (GSK706769 & KALETRA)

Completed
  • Infection, Human Immunodeficiency Virus
  • GSK706769 & KALETRA
  • Buffalo, New York
    GSK Investigational Site
Jul 19, 2017

Infection, Human Immunodeficiency Virus Trial in Austin (GSK1349572 formulation AP, GSK1349572 formulation AW, GSK1349572

Completed
  • Infection, Human Immunodeficiency Virus
  • GSK1349572 formulation AP
  • +2 more
  • Austin, Texas
    GSK Investigational Site
Jun 8, 2017

Infection, Human Immunodeficiency Virus Trial in Baltimore (GSK1349572, Rifampin, Rifabutin)

Completed
  • Infection, Human Immunodeficiency Virus
  • Baltimore, Maryland
    GSK Investigational Site
Jun 6, 2017

Infections, Human Immunodeficiency Virus and Herpesviridae, Infection, Human Immunodeficiency Virus Trial in Buffalo (GSK2248761

Completed
  • Infections, Human Immunodeficiency Virus and Herpesviridae
  • Infection, Human Immunodeficiency Virus
  • GSK2248761 WBM Capsule
  • +4 more
  • Buffalo, New York
    GSK Investigational Site
Jun 6, 2017

Fractures Stratified by HIV and Antiretroviral Therapy Status

Completed
  • Fracture
  • Infection, Human Immunodeficiency Virus
  • No Antiretroviral (ARV) Drug Exposure
  • Any Antiretroviral (ARV) Drug Exposure
  • (no location specified)
May 31, 2017

PENTA Fosamprenavir Study

Completed
  • Infection, Human Immunodeficiency Virus
  • Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)
  • (no location specified)
May 31, 2017

Infection, Human Immunodeficiency Virus Trial in Baltimore (GSK2838232 PIB (SDD), GSK2838232 PIB (API), Placebo)

Terminated
  • Infection, Human Immunodeficiency Virus
  • GSK2838232 PIB (SDD)
  • +3 more
  • Baltimore, Maryland
    GSK Investigational Site
May 12, 2017

Infection, Human Immunodeficiency Virus Trial in Overland Park (Lamivudine, Sorbitol)

Completed
Has Results
  • Infection, Human Immunodeficiency Virus
  • Overland Park, Kansas
    GSK Investigational Site
May 3, 2017

Infection, Human Immunodeficiency Virus Trial in Dallas (BMS-663068 (1 tablet at 600 mg), BMS-663068 (4 tablets at 150 mg each

Completed
  • Infection, Human Immunodeficiency Virus
  • BMS-663068 (1 tablet at 600 mg)
  • BMS-663068 (4 tablets at 150 mg each tablet)
  • Dallas, Texas
    GSK Investigational Site
May 12, 2017

Infection, Human Immunodeficiency Virus Trial in Baltimore (GSK2838232, Placebo, Ritonavir)

Terminated
  • Infection, Human Immunodeficiency Virus
  • Baltimore, Maryland
    GSK Investigational Site
May 5, 2017

Infection, Human Immunodeficiency Virus Trial in Baltimore (GSK2838232, Placebo, Ritonavir)

Completed
  • Infection, Human Immunodeficiency Virus
  • Baltimore, Maryland
    GSK Investigational Site
May 5, 2017

Infection, Human Immunodeficiency Virus Trial in Ruddington Fields (BMS-955176)

Completed
  • Infection, Human Immunodeficiency Virus
  • Ruddington Fields, Nottinghamshire, United Kingdom
    GSK Investigational Site
Apr 13, 2017

Infection, Human Immunodeficiency Virus Trial in Worldwide (Continued Access Arm)

No longer available
  • Infection, Human Immunodeficiency Virus
  • Continued Access Arm
  • Rosario, Santa Fe, Argentina
  • +27 more
Apr 4, 2017

Infection, Human Immunodeficiency Virus Trial in Austin (DTG, BCV, TVR)

Completed
  • Infection, Human Immunodeficiency Virus
  • Austin, Texas
    GSK Investigational Site
Mar 27, 2017

Infection, Human Immunodeficiency Virus Trial in Austin (Dolutegravir, BMS955176)

Completed
  • Infection, Human Immunodeficiency Virus
  • Austin, Texas
    GSK Investigational Site
Jan 17, 2017

Infection, Human Immunodeficiency Virus Trial in Overland Park (Dolutegravir 50 mg tablet, Lamivudine 300 mg tablet,

Completed
  • Infection, Human Immunodeficiency Virus
  • Dolutegravir 50 mg tablet
  • +3 more
  • Overland Park, Kansas
    GSK Investigational Site
Jan 16, 2017

Infection, Human Immunodeficiency Virus Trial in Baltimore (GSK2838232 PIB, GSK2838232 IR1, GSK2838232 IR2)

Completed
  • Infection, Human Immunodeficiency Virus
  • GSK2838232 PIB
  • +4 more
  • Baltimore, Maryland
    GSK Investigational Site
Jan 16, 2017

Infection, Human Immunodeficiency Virus Trial in Overland Park (Cabotegravir 30 mg)

Completed
  • Infection, Human Immunodeficiency Virus
  • Cabotegravir 30 mg
  • Overland Park, Kansas
    GSK Investigational Site
Jan 12, 2017

Infection, Human Immunodeficiency Virus Trial in Worldwide (GW433908, ritonavir)

Unknown status
Has Results
  • Infection, Human Immunodeficiency Virus
  • Jacksonville, Florida
  • +14 more
Nov 28, 2016